Articles by Harry G. Brittain, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Harry G. Brittain, PhD

Harry G. Brittain, PhD


Harry G. Brittain, PhD, is the director of the Center for Pharmaceutical Physics and a member of Pharmaceutical Technology's editorial advisory board. 10 Charles Rd., Milford, NJ 08848, tel. 908.996.3509, fax 908.996.3560, hbrittain@centerpharmphysics.com

Articles
The Path to Product Stability Is through Water
December 2, 2009

Readers can learn about the importance of measuring and controlling water activity in a comprehensive new book.

Strategy for the Prediction and Selection of Drug Substance Salt Forms
October 2, 2007

Through consideration of the ionic equilibria of acids and bases, one may readily calculate the formation constant of a salt species solely on the basis of knowledge of the pKA value of the acid and the pKB value of the base.

Determination by Analytical Sieving: Particle-Size Distribution, Part III
December 2, 2002

The author discusses the use of analytical sieving to determine the size distribution of granular and course powders and describes proper sieve construction and USP General Test {786}.

Particle-Size Distribution II: The Problem of Sampling Powdered Solids
July 1, 2002

Dynamic powder-sampling methods may be the best techniques for obtaining a representative sample for determining particle-size distribution.

What Is the "Correct" Method to Use for Particle-Size Determination?
July 1, 2001

Appropriate sampling procedures, proper preparation, and correct instrumental parameters may yield differing, but correct, results.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FindPharma Custom Search
Click here